Deborah S. Yokoe*

, Gary A. Noskin†, Susan M. Cunningham†, Gianna Zuccotti‡, Theresa Plaskett‡, Victoria J. Fraser§, Margaret A. Olsen§, Jerome I. Tokars¶, Steven Solomon¶, Trish M. Perl#, Sara E. Cosgrove#, Richard S. Tilson*, Maurice Greenbaum**, David C. Hooper††, Kenneth E. Sands‡‡, John Tully§§, Loreen A. Herwaldt¶¶, Daniel J. Diekema¶¶, Edward S. Wong##, Michael Climo##, and Richard Platt***
Author affiliations: *Brigham and Women's Hospital, Boston, Massachusetts, USA; †Northwestern University, Chicago, Illinois, USA; ‡Memorial Sloan-Kettering Cancer Center, New York, New York, USA; §Washington University School of Medicine, St. Louis, Missouri, USA; ¶Centers for Disease Control and Prevention, Atlanta, Georgia, USA; #Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; **North Shore Medical Center-Salem Hospital, Salem, Massachusetts, USA; ††Massachusetts General Hospital, Boston, Massachusetts, USA; ‡‡Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; §§Mount Auburn Medical Center, Cambridge, Massachusetts, USA; ¶¶University of Iowa Carver College of Medicine, Iowa City, Iowa, USA; ##McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA; ***Harvard Pilgrim Health Care, Boston, Massachusetts, USA
Main Article
Table A4
Percentage of patients who underwent CABG procedures and who met the antimicrobial exposure or diagnosis code screening criteriaa
| Hospital |
% of CABG patients with
|
| 9-day antimicrobial threshold |
7-day antimicrobial threshold |
Diagnosis code criteria |
9-day antimicrobial or
diagnosis code criteria (%) |
| 1A |
13.7 |
–b |
2.2 |
13.8 |
| 1B |
21.0 |
–b |
7.4 |
22.2 |
| 1C |
12.9 |
–b |
4.9 |
13.2 |
| 1D |
5.2 |
–b |
3.5 |
6.4 |
| Pooled |
15.2 |
–b |
4.5 |
15.8 |
| 2A |
18.6 |
18.9 |
3.7 |
18.6 |
| 2B |
17.3 |
21.0 |
6.2 |
18.2 |
| 2C |
15.0 |
17.0 |
3.9 |
15.0 |
| 2D |
22.9 |
31.5 |
5.3 |
23.6 |
| 2E |
17.4 |
18.2 |
3.7 |
17.9 |
| 2F |
22.6 |
25.3 |
6.0 |
22.6 |
| Pooled |
19.1 |
23.1 |
4.6 |
19.6 |
Main Article
Top of Page